Pharmacy

Medicare Part D prescription drug plan premiums will hold flat at $32.50 a month in 2016, the Centers for Medicare and Medicaid Services announced on Wednesday, despite ballooning costs for the federal program.

Though antibiotic-resistant "superbugs" aren't new, their rise in U.S. healthcare institutions is leading hospitals to stock up on supplies to combat them.

Rebounding from a tough couple of years due to lack of availability of generic drugs, many healthcare facilities are weighing their options.

Ambitious diagnostics company will bring its low-cost blood testing to Medicaid patients.

Farid Fata admitted to prescribing and administering unnecessary aggressive chemotherapy, cancer treatments and infusion therapies to patients to increase his billings to Medicare and private insurance companies.

The testing company that could upend America's diagnostics market will partner with Capital BlueCross in Harrisburg, Pennsylvania, to bring the company's new direct-to-consumer blood testing options to the insurer's 1.3 million members.

The Government Accountability Office believes Congress should slash the financial incentives the government pays hospitals in the 340B drug program, it said in a new report, over concerns that disproportionate share hospitals are prescribing more than other facilities.

Harvard Drug Group mainly distributes generic pharmaceuticals and pulled in more than $450 million in revenue in fiscal 2014.

Major cancer centers topped the list with tens of millions in payments and services from pharmaceutical giants.

Several teaching hospitals raked millions in payments from device and drug manufacturers in 2014, according to new data from the Centers for Medicare and Medicaid Services released Tuesday that showed drug and medical device makers made close to $6.5 billion in payments to healthcare providers in 2014.